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Development of Kaposi sarcoma requires infection with human 
herpesvirus 8, but not all human herpesvirus 8–infected individuals 
develop Kaposi sarcoma. There is good evidence of a strong asso-
ciation between Kaposi sarcoma and immune suppression because 
risk of Kaposi sarcoma is increased as immune function is progres-
sively  impaired  in  HIV-infected  individuals  (1,2),  and  HIV-
infected individuals with intact immune systems appear to be at a 
relatively low risk of Kaposi sarcoma (3).
This association has been further supported by the fact that, since 
the  introduction  of  combination  antiretroviral  therapy  (cART), 
declines in the risk of Kaposi sarcoma have been reported (1,4–7) as a 
result of the suppression of HIV viral replication and improving im-
mune function, and are in line with declines observed in the rate   
of other AIDS-defining conditions (8,9) [ie, a set of opportunistic 
infections  and  malignancies  according  to  the  definition  of  the 
European Centre for the epidemiological monitoring of AIDS (10)]. 
It is further supported by studies (11,12) that have documented Kaposi 
sarcoma regression after successful suppression of HIV-1 RNA and 
increases in CD4+ lymphocyte counts after initiation of cART.
Given  that  previous  reports  (13–16)  have  described  Kaposi 
sarcoma lesions among cART-treated persons whose HIV RNA is 
not detectable by current assays and who have a high CD4 cell 
count, the role of immunosuppression and of determinants of risk 
for  Kaposi  sarcoma  since  the  introduction  of  cART  remains 
unknown. A cluster of Kaposi sarcoma cases among nine seemingly 
unrelated HIV-infected homosexual men, as described (13), ap-
pears  to  indicate  that  a  new  form  of  Kaposi  sarcoma  may  be 
emerging because the account was akin to the initial reports of 
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  Background  Despite the success of combination antiretroviral therapy (cART) in reducing the incidence of Kaposi sarcoma, 
HIV-infected individuals who have responded to treatment continue to be diagnosed with Kaposi sarcoma. We 
examine factors associated with the incidence of Kaposi sarcoma among cART-treated HIV-infected homosexual 
men and changes in their survival after its diagnosis over calendar time.
  Methods  Data were from HIV-infected homosexual men with well-estimated dates of HIV seroconversion (ie, change in 
status from being HIV negative to having HIV antibodies detected). Incidence of Kaposi sarcoma was calculated. 
We used Kaplan–Meier methods to determine survival after Kaposi sarcoma diagnosis in three calendar pe-
riods: before 1996, 1996–2000, and 2001–2006. Poisson models were used to examine the effect of risk factors 
such as current and nadir CD4 cell count (ie, the lowest CD4 cell count ever recorded for a person), duration of 
infection, and age at diagnosis for Kaposi sarcoma incidence in cART-treated men. All statistical tests were 
two-sided.
  Results  Among the 9473 men, 555 were diagnosed with Kaposi sarcoma in the period 1986–2006, of whom 319 died. 
The percentage surviving 24 months after Kaposi sarcoma diagnosis rose statistically significantly during the 
study period from 35% (95% confidence interval [CI] = 29% to 42%) before 1996 to 84% (95% CI = 76% to 90%) 
in 1996–2000 and to 81% (95% CI = 70% to 88%) in 2001–2006 (P < .001). Seventy men were diagnosed with 
Kaposi sarcoma after starting cART. Current (ie, within 6 months) CD4 cell count was associated with incidence 
of Kaposi sarcoma among cART-treated men (rate ratios [RRs] = 18.91, 95% CI = 8.50 to 42.09, for CD4 level 
category <200 cells per cubic millimeter; RR = 3.55, 95% CI = 1.40 to 9.00, for 200–349 cells per cubic millimeter; 
and RR = 4.11, 95% CI = 1.74 to 9.70, for 350–499 cells per cubic millimeter; all compared with ≥500 cells per 
cubic millimeter). After adjustment for current CD4 cell count, HIV infection duration, age, or nadir CD4 cell 
count was not associated with Kaposi sarcoma incidence.
  Conclusions  Among cART-treated HIV-infected homosexual men, current CD4 cell count was the factor most strongly asso-
ciated with the incidence of Kaposi sarcoma. Survival estimates after Kaposi sarcoma diagnosis have improved 
over time.
      J Natl Cancer Inst 2010;102:784–792jnci.oxfordjournals.org    JNCI | Articles 785
Kaposi sarcoma clusters that were described in the pre-AIDS liter-
ature  in  the  1980s  (17).  Although  Kaposi  sarcoma  is  not  rare 
among cART-treated HIV-infected individuals (15,16), the ques-
tion remains as to whether the risk of Kaposi sarcoma persists even 
when the HIV infection is under control. As the gap in life expec-
tancies between people with HIV and uninfected individuals with 
similar age and sex narrows (18), a deficient immune system over 
the long term may be reflected in an increase in the incidence of 
Kaposi sarcoma or other cancers among HIV-infected individuals 
who have responded to cART.
Although it has been proposed (13,15) that the risk of Kaposi 
sarcoma among HIV-infected individuals who have responded to 
cART may be a function of age and/or the duration of HIV infec-
tion,  this  association  has  not,  to  our  knowledge,  been  fully 
explored. We, therefore, used a large dataset of men with well-
estimated dates of HIV seroconversion (ie, change in status from 
being HIV antibody negative to having HIV antibody detected) to 
evaluate whether the duration of HIV infection and age were asso-
ciated with risk of Kaposi sarcoma among HIV-infected homo-
sexual men after the initiation of cART. Associations of aspects   
of  immunosuppression  with  risk  were  also  explored,  including 
current CD4 cell count, current HIV RNA level, nadir CD4 cell 
count (ie, the lowest CD4 cell count ever recorded for an indi-
vidual), and time-weighted average CD4 cell count throughout 
follow-up since HIV seroconversion. We also explored associa-
tions between various CD4 cell levels and Kaposi sarcoma inci-
dence among nontreated and cART-treated HIV-infected men to 
evaluate  the  extent  to  which  the  association  between  starting 
cART and risk of Kaposi sarcoma may be mediated through CD4 
cell  count.  Finally,  because  individuals  who  are  known  to  have 
undergone HIV seroconversion are, by definition, diagnosed and 
come under medical care after infection, we compared our esti-
mates  of  survival  after  a  Kaposi  sarcoma  diagnosis  with  those 
derived from other cohorts of patients with prevalent HIV infec-
tion to provide information on whether late diagnosis of HIV is 
associated with prognosis for Kaposi sarcoma.
Subjects and Methods
Study Subjects and Database
We  used  data  from  HIV-infected  homosexual  men  with  well- 
estimated dates of HIV seroconversion from the Concerted Action 
of Seroconversion to AIDS and Death in Europe (CASCADE) 
Collaboration. CASCADE has been described in detail elsewhere 
(19). Briefly, it is currently a collaboration of 25 cohorts of persons 
with well-estimated dates of HIV seroconversion from Europe, 
Australia, Canada, and sub-Saharan Africa. The date of serocon-
version is estimated by various methods: most frequently (ie, 94% 
of men) as the midpoint between the last negative and first positive 
HIV antibody test dates with a maximum of 3 years between test 
dates, laboratory evidence of seroconversion (real-time polymerase 
chain  reaction  positivity  in  the  absence  of  HIV  antibodies  or 
antigen positivity with fewer than four bands on an immunoblot) 
(ie, 4%), or the date of a seroconversion illness (and an earlier 
documented negative HIV) (ie, 2%). For 117 homosexual men 
(148 antibody tests), the last negative and first positive tests were 
obtained  retrospectively  (ie,  before  the  availability  of  the  HIV 
cONteXt AND cAVeAtS
Prior knowledge
Although combination antiretroviral therapy (cART) has reduced 
Kaposi sarcoma incidence among HIV-infected individuals, some 
who respond to cART still develop Kaposi sarcoma.
Study design
Data from HIV-infected homosexual men with well-estimated dates 
of HIV seroconversion were used to calculate Kaposi sarcoma inci-
dence  and  survival  after  Kaposi  sarcoma  diagnosis.  Poisson 
models  were  used  to  examine  associations  of  risk  factors  with 
Kaposi sarcoma incidence.
Contribution
Among the cohort of 9473 men, 555 were diagnosed with Kaposi 
sarcoma in the period 1986–2006 and 319 of them died. Survival for 
24 months after diagnosis rose substantially during the study pe-
riod. Seventy men were diagnosed with Kaposi sarcoma after start-
ing cART. Low CD4 cell count within 6 months of diagnosis (ie, 
current CD4 cell count) was associated with increased incidence of 
Kaposi sarcoma among cART-treated men.
Implications
Among cART-treated HIV-infected homosexual men, current CD4 
cell count was the factor most strongly associated with the inci-
dence of Kaposi sarcoma. Survival after Kaposi sarcoma diagnosis 
improved during the study period.
Limitations
No information on treatment adherence was available. Associations 
between various factors and risk of Kaposi sarcoma were based on 
70 patients, and follow-up was 4.5 years. Men who start cART treat-
ment may be sicker and at higher risk of Kaposi sarcoma. Cause of 
death was not available.
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antibody  test  in  1985)  from  stored  blood  sample.  All  cohorts 
received approval from their individual ethics review boards except 
for the Danish cohort, which received approval from the National 
Data Registry Surveillance Agency because Danish law allowed 
collection and pooling of anonymized clinical data with approval 
from this agency alone. Two ethics review boards deemed their 
cohort participants exempt from providing signed informed con-
sent.  Signed  informed  consent  was  obtained  from  all  others. 
Approval was also given by all ethics review boards to pool anony-
mized data for analyses and dissemination.
Because Kaposi sarcoma is caused by human herpesvirus 8 and 
because the prevalence of this virus is higher in HIV-infected homo-
sexual men than in other HIV-infected groups (20,21), we restricted 
analyses to the men in this dataset who were infected through sex 
between men, who were aged 16 years or older at seroconversion, and 
who had at least 1 day of follow-up. Data were pooled in September 
2007 and did not include the sub-Saharan African cohorts who were 
not part of the CASCADE collaboration at that time.
Statistical Methods
We studied HIV-infected homosexual men in our cohort who 
were diagnosed with Kaposi sarcoma in three calendar periods: 786   Articles | JNCI  Vol. 102, Issue 11  |  June 2, 2010 
before 1996, which reflects the period before the introduction of 
cART; 1996–2000, which reflects treatment with a cART reg-
imen  that  included  only  unboosted  protease  inhibitors;  and 
2001–2006, which reflects treatment with a cART regimen that 
included boosted protease inhibitors and non-nucleoside reverse 
transcriptase inhibitors. We investigated changes over time in 
subject characteristics, particularly changes in the median CD4 
cell count and the level of HIV RNA at approximately the time 
of  Kaposi  sarcoma  diagnosis  (defined  as  a  period  of  up  to   
6 months before and 1 month after Kaposi sarcoma diagnosis).   
We also explored changes in survival (ie, all-cause mortality) after 
Kaposi sarcoma diagnosis by using Kaplan–Meier estimates to 
determine cumulative survival probability in each calendar pe-
riod. Time was measured from the date of Kaposi sarcoma diag-
nosis. In each calendar period, follow-up for men who remained 
event free was censored on the last day of that period or the date 
last known alive, whichever was earlier. If a person’s follow-up 
extended across more than one of the three calendar periods, the 
man  was  censored  at  the  end  of  the  period  in  which  he  was 
diagnosed.
We  calculated  incidence  rates  of  Kaposi  sarcoma  per  1000 
person-years of follow-up, according to current CD4 cell count for 
two follow-up groups: the naive follow-up group, who had not 
been  treated  with  any  antiretroviral  treatment,  and  the  “cART 
group,” which included patients who received regimens containing 
either three or more drugs from at least two classes or at least three 
nucleoside reverse transcriptase inhibitors, at least one of which 
was  either  tenofovir  or  abacavir.  A  man  who  started  on  cART 
contributed  to  both  follow-up  groups:  to  the  naive  follow-up 
group for the time before he started cART and to cART follow-up 
group from then on. Follow-up under non-cART regimens was 
ignored because this is no longer part of clinical care of HIV-
infected patients. Follow-up began at the date of estimated sero-
conversion or the date of enrollment into a cohort, whichever was 
later. For the naive follow-up group, follow-up continued until the 
date of diagnosis of Kaposi sarcoma, the date of last visit, death, or 
the initiation of any antiretroviral therapy, whichever was earlier. 
For the cART follow-up group, follow-up continued until the date 
of Kaposi sarcoma, the date of last visit, or death, whichever was 
earlier. In a Poisson regression model, we included cART status as 
an indicator variable, with an interaction term between the CD4 
cell count level and cART status and adjustment for current age as 
a time-updated covariate.
We explored the relationship of duration of HIV infection and 
current  age  to  the  risk  of  Kaposi  sarcoma  among  those  in  the 
cART  follow-up  group,  with  adjustment  for  current  (within   
6 months) CD4 cell count and current (within 12 months) HIV 
RNA  (defined  as  time-updated  variables),  whether  the  initial 
cART regimen contained a protease inhibitor (yes or no), whether 
there was a pre-cART treatment (yes or no), and the time interval 
since the initiation of cART (≤1 year or >1 year). The prognostic 
importance  of  these  factors  was  assessed  by  use  of  Wald  tests. 
When a CD4 cell count measurement was not followed by a sub-
sequent  measurement  within  6  months,  the  man  was  excluded 
from the risk set until the date that a new CD4 cell count became 
available. A longer period for HIV RNA level to remain current 
was chosen because this marker tends to exhibit smaller changes 
over time (22,23). Duration of HIV infection, current age, current 
CD4 cell count, and current HIV RNA were treated as contin-
uous. Because some of the relationships between covariates and the 
risk  of  Kaposi  sarcoma  may  not  be  linear,  we  transformed  the 
covariates  where  necessary  by  using,  for  example,  the  natural 
logarithm, square root, and fractional polynomials to test whether 
the linearity assumption was appropriate (24). However, to ease 
the interpretation of the results, current CD4 cell count was cate-
gorized  into  four  categories  (<200,  200–349,  350–499,  or  ≥500 
cells per cubic millimeter). To avoid selective drop out of patients 
with worse prognosis (ie, those failing to respond to cART), we 
assumed that once started, patients remained on treatment and we 
ignored subsequent changes of treatment and treatment interrup-
tion. Men who were diagnosed with Kaposi sarcoma on the date of 
cART initiation were excluded. All HIV RNA measurements that 
were less than the detection limit were replaced by half of the 
assay’s cutoff value, and values that were greater than the upper 
limit were replaced by the cutoff value.
To explore the role of history of immunosuppression, associa-
tions  of  nadir  CD4  cell  count  at  cART  initiation  and  time-
weighted average CD4 cell count with the incidence of Kaposi 
sarcoma after cART initiation were investigated. At each time, 
average  CD4  counts  were  determined  by  estimating  the  area 
under the curve when CD4 count was plotted over time. The 
time-weighted average was obtained by dividing the area under 
the curve by the time since seroconversion and was used as a time-
updated covariate in the model. The nadir CD4 cell count may be 
an important marker if previous immune system damage is related 
to increased risk of Kaposi sarcoma, even after subsequent im-
provement in this cell count, although the time-weighted average 
CD4 cell count can be viewed as a summary measure of the overall 
immunodeficiency  history.  All  models  were  adjusted  for  the 
potential confounders described above in the model for current 
CD4  cell  count.  Nonnested  models  were  compared  by  use  of 
Akaike  information  criterion  (25).  All  statistical  tests  were 
two-sided. P values of less than .05 were considered to be statisti-
cally significant.
results
Among the 9473 homosexual men in CASCADE, 555 were diag-
nosed with Kaposi sarcoma in the period from January 1, 1986, 
through December 31, 2006; characteristics of these men at their 
diagnosis of Kaposi sarcoma are presented in Table 1. As expected, 
because of the increased survival after the widespread availability 
of cART in 1996, those diagnosed with Kaposi sarcoma after the 
introduction of cART had been infected with HIV for increasingly 
longer periods. Median CD4 cell count at Kaposi sarcoma diagno-
sis rose statistically significantly over time from 106 cells per cubic 
millimeter  (interquartile  range  [IQR]  =  30–231  cells  per  cubic 
millimeter) before 1996 to 195 cells per cubic millimeter (IQR = 
31–352 cells per cubic millimeter) in 1996–2000 and to 252 cells 
per cubic millimeter (IQR = 45–382 cells per cubic millimeter) in 
2001–2006 (P < .001). The nadir CD4 cell count also increased 
statistically significantly from before 1996 through 2006 (P = .003), 
but no change in the level of HIV RNA at Kaposi sarcoma diagno-
sis was observed during the study period (P = .98).jnci.oxfordjournals.org    JNCI | Articles 787
Effects of Calendar Year on Mortality and Survival 
Estimates
Among the 555 men diagnosed with Kaposi sarcoma, 319 (57%) 
had died by the end of 2006. Most deaths (261 [82%]) occurred 
before 1996, with 42 deaths in 1996–2000 and 16 deaths in 2001–
2006. The proportion of men with at least a 24-month survival 
after Kaposi sarcoma diagnosis rose markedly over time from 35% 
(95% confidence interval [CI] = 29% to 42%) in 1986–1995 to 
84% (95% CI = 76% to 90%) in 1996–2000 and to 81% (95% CI = 
70%  to  88%)  in  2001–2006  (P  <  .001,  log-rank  test).  Among 
patients who were diagnosed with Kaposi sarcoma in 2001–2006, 
we found cumulative survival probabilities at 24 months of 71% 
(95% CI = 55% to 83%) for those with a CD4 cell count of less 
than 300 cells per cubic millimeter and 94% (95% CI = 77% to 
98%) for those with a CD4 cell count of 300 cells per cubic milli-
meter or more at Kaposi sarcoma diagnosis. Despite the few deaths 
(13 deaths in the men with a CD4 cell count of <300 cells per cubic 
millimeter and three deaths in men with CD4 cell count of ≥300 
cells per cubic millimeter at Kaposi sarcoma diagnosis), the sur-
vival difference between the two follow-up groups was statistically 
significant (P = .021, log-rank test).
Incidence of Kaposi Sarcoma by cART Status
A  total  of  7873  homosexual  men  in  the  naive  follow-up  group 
contributed  23 352.29  person-years  of  follow-up,  of  whom  192 
developed Kaposi sarcoma during the study period. A total of 4199 
patients  in  the  cART  follow-up  group  contributed  19 535.7   
person-years, of whom 70 developed Kaposi sarcoma.
We fit a Poisson regression model with an interaction between 
a cART indicator and the current CD4 count after adjustment for 
age.  According  to  the  fractional  polynomial  approach  (24),  the 
square  root  transformation  of  current  CD4  count  provided  an 
adequate fit for the incidence of Kaposi sarcoma. According to this 
model, at the same current CD4 level, there is a higher risk of 
Kaposi sarcoma in the naive follow-up group than in the cART 
follow-up group but only with borderline statistical significance   
(P for interaction = .067). For simplicity, we report rates of Kaposi 
sarcoma  by  current  CD4  cell  level  (<200,  200–349,  350–499,   
or ≥500 cells per cubic millimeter) (Table 2). Incidence rates of 
Kaposi sarcoma increased as the level of CD4 cells decreased in 
both naive and cART follow-up groups. Overall, the incidence rate 
of Kaposi sarcoma was lower in the cART follow-up group (3.58 
diagnoses of Kaposi sarcoma per 1000 person-years) than in the 
naive follow-up group (8.22 diagnoses per 1000 person-years), as 
expected. There were 81 diagnoses of Kaposi sarcoma in the naive 
follow-up group during 8681.7 person-years and 13 in the cART 
follow-up group during 1946.1 person-years of follow-up while 
current CD4 cell count was missing, giving crude incidence rates 
of 9.33 and 6.68 diagnoses of Kaposi sarcoma per 1000 person-
years, respectively. To explore the effect of the missing CD4 cell 
count data, we took the mean value of the last and first available 
measurements to obtain median values for the missing CD4 cell 
counts of 525 cells per cubic millimeter (IQR = 401–682 cells per 
cubic millimeter) for the naive follow-up group and 522 cells per 
cubic millimeter (IQR = 348–717 cells per cubic millimeter) for 
the cART follow-up group.
Factors Associated With the Incidence of Kaposi Sarcoma 
After Initiation of cART
In  the  cART  follow-up  group,  70  men  were  diagnosed  with 
Kaposi sarcoma, with a median CD4 cell count at diagnosis of 240 
cells per cubic millimeter (IQR = 82–405 cells per cubic milli-
meter) and a median log10 HIV RNA level of 4.24 (IQR = 2.31–
5.28)  during  a  median  follow-up  of  4.5  years  (IQR  =  1.9–7.3 
years). The median duration of infection with HIV was 7 years 
(IQR = 4–9 years), the median age at Kaposi sarcoma diagnosis 
was 37 years (IQR = 32–43 years), and the time since starting 
cART was 3 years (IQR = 1–5 years). Among these 70 men, nine 
were diagnosed with Kaposi sarcoma and had a CD4 level of more 
than 300 cells per cubic millimeter and a HIV RNA level that had 
remained less than 500 copies per milliliter for at least 2 years 
before their diagnosis of Kaposi sarcoma. Among these nine men, 
the median duration of infection was 5 years (IQR = 2–8 years) 
and the median age at Kaposi sarcoma diagnosis was 39 years 
(IQR = 36–43 years).
Crude incidence rates of Kaposi sarcoma fell slightly in the first 
year after starting cART from 8.22 Kaposi sarcoma diagnoses per 
1000 person-years in the naive follow-up group (ie, before starting 
any antiretroviral therapy) to 6.67 per 1000 person-years in the 
cART follow-up group. This decrease was followed by an even 
sharper decline thereafter, with the incidence rate of Kaposi sar-
coma remaining at approximately 2.5 Kaposi sarcoma diagnoses 
per  1000  person-years  from  approximately  1  year  of  follow-up 
through at least 5 years of follow-up (Figure 1).
Table 1. Characteristics of patients at diagnosis of Kaposi sarcoma (KS) according to calendar period of diagnosis*
Characteristic
Calendar period of KS diagnosis
Pre-1996 1996–2000 2001–2006
No. 332 133 90
Median age, y (IQR) 35 (31–43) 36 (32–42) 37 (33–44)
Median duration of HIV infection, y (IQR) 4.5 (2.9–6.3) 5.5 (3.4–7.8) 6.5 (3.1–9.4)
Median CD4 cell count, cells per cubic millimeter (IQR) 106 (30–231) 195 (31–352) 252 (45–382)
Median nadir CD4 cell count, cells per cubic millimeter (IQR) 20 (6–90) 58 (12–215) 161 (35–287)
Median HIV RNA, log10 copies per milliliter (IQR) — 4.7 (3.6–5.5) 4.9 (4.4–5.3)
ART naive,† No. (%) 156 (47) 56 (42) 31 (34)
*  CD4 cell count and HIV RNA measurements were recorded up to 6 months before and 1 month after KS diagnosis date. Numbers of individuals with missing 
data on CD4 cell count (and HIV RNA level) were 58 (—) before 1996, 14 (66) for 1996–2000, and four (three) for 2001–2006. IQR = interquartile range;  
nadir = lowest value ever recorded.
†  These patients had no antiretroviral treatment before their diagnosis of KS.788   Articles | JNCI  Vol. 102, Issue 11  |  June 2, 2010 
The  duration  of  HIV  infection  was  not  associated  with  the 
incidence of Kaposi sarcoma in the cART follow-up group (rate 
ratio  [RR]  per  additional  year  =  0.97,  95%  CI  =  0.90  to  1.05,   
P = .44) (Table 3). Current levels of CD4 cells and HIV RNA 
were, however, associated with the incidence of Kaposi sarcoma, 
with lower CD4 cell levels being associated with higher incidence 
rates  of  Kaposi  sarcoma.  More  specifically,  current  (ie,  within   
6 months) CD4 cell count was associated with crude incidence   
of Kaposi sarcoma among cART-treated men (RR = 18.91, 95% 
CI = 8.50 to 42.09, for CD4 level category <200 cells per cubic 
millimeter; RR = 3.55, 95% CI = 1.40 to 9.00, for 200–349 cells 
per cubic millimeter; and RR = 4.11, 95% CI = 1.74 to 9.70, for 
350–499 cells per cubic millimeter; all compared with ≥500 cells 
per cubic millimeter). Although the crude incidence rate of Kaposi 
sarcoma was statistically significantly lower after the first year in 
which cART was initiated (P = .003), when we adjusted for current 
CD4 cell level and HIV RNA, the incidence rate of Kaposi sar-
coma  was  not  associated  with  duration  of  cART  of  more  than   
1 year as compared with duration of 1 year or less (RR = 0.87, 95% 
CI = 0.47 to 1.61, P = .66), the presence of protease inhibitor in the 
cART regimen (P = .44), or being antiretroviral treatment naive at 
cART initiation (P = .16).
In multivariable models including other measures of immuno-
suppression mediated through CD4 cell count, among the cART 
follow-up group, the current CD4 cell count was more strongly 
associated with risk of Kaposi sarcoma than the nadir CD4 cell 
count or the time-weighted average CD4 count (data not shown). 
Although there was a borderline statistically significantly associa-
tion between the nadir CD4 cell count at cART initiation and the 
risk of Kaposi sarcoma (P = .06), after adjusting for current CD4 
cell count, which appeared to be strongly associated with the risk 
of Kaposi sarcoma (P < .001), the association disappeared (P = .59) 
(Table  4),  as  did  that  for  the  time-weighted  average  CD4  cell 
count (P = .16).
T
a
b
l
e
 
2
.
 
K
a
p
o
s
i
 
s
a
r
c
o
m
a
 
(
K
S
)
 
i
n
c
i
d
e
n
c
e
 
r
a
t
e
s
 
b
y
 
c
u
r
r
e
n
t
 
C
D
4
 
c
e
l
l
 
c
o
u
n
t
 
s
t
a
t
u
s
 
a
m
o
n
g
 
t
h
e
 
n
a
i
v
e
 
f
o
l
l
o
w
-
u
p
 
g
r
o
u
p
 
a
n
d
 
t
h
e
 
c
o
m
b
i
n
a
t
i
o
n
 
a
n
t
i
r
e
t
r
o
v
i
r
a
l
 
t
h
e
r
a
p
y
 
(
c
A
R
T
)
 
 
f
o
l
l
o
w
-
u
p
 
g
r
o
u
p
*
C
D
4
 
s
t
a
t
u
s
,
 
c
e
l
l
s
 
p
e
r
 
c
u
b
i
c
 
m
i
l
l
i
m
e
t
e
r
N
a
i
v
e
 
f
o
l
l
o
w
-
u
p
 
g
r
o
u
p
c
A
R
T
 
f
o
l
l
o
w
-
u
p
 
g
r
o
u
p
R
R
†
 
(
9
5
%
 
C
I
)
P
e
r
s
o
n
-
y
e
a
r
s
K
S
 
e
v
e
n
t
s
,
 
N
o
.
C
r
u
d
e
 
i
n
c
i
d
e
n
c
e
 
r
a
t
e
P
e
r
s
o
n
-
y
e
a
r
s
K
S
 
e
v
e
n
t
s
,
 
N
o
.
C
r
u
d
e
 
i
n
c
i
d
e
n
c
e
 
r
a
t
e
<
2
0
0
5
7
3
.
3
4
2
7
3
.
2
7
1
4
1
9
.
1
2
4
1
6
.
9
1
4
.
3
4
 
(
2
.
6
5
 
t
o
 
7
.
2
7
)
2
0
0
–
3
4
9
2
4
0
8
.
9
2
3
9
.
5
5
3
1
4
6
.
9
1
0
3
.
1
8
3
.
0
5
 
(
1
.
4
5
 
t
o
 
6
.
4
2
)
3
5
0
–
4
9
9
4
2
5
8
.
6
2
8
6
.
5
7
4
0
7
8
.
9
1
5
3
.
6
8
1
.
8
1
 
(
0
.
9
7
 
t
o
 
3
.
4
2
)
≥
5
0
0
7
4
2
6
.
5
1
8
2
.
4
2
8
9
4
5
.
2
8
0
.
8
9
2
.
7
6
 
(
1
.
1
9
 
t
o
 
6
.
3
6
)
M
i
s
s
i
n
g
8
6
8
4
.
0
8
1
9
.
3
3
1
9
4
5
.
6
1
3
6
.
6
8
T
o
t
a
l
2
3
 
3
5
1
.
3
1
9
2
8
.
2
2
1
9
 
5
3
5
.
7
7
0
3
.
5
8
*
 
C
r
u
d
e
 
K
S
 
i
n
c
i
d
e
n
c
e
 
r
a
t
e
s
 
a
r
e
 
r
e
p
o
r
t
e
d
 
a
s
 
n
u
m
b
e
r
 
o
f
 
K
S
 
d
i
a
g
n
o
s
e
s
 
p
e
r
 
1
0
0
0
 
p
e
r
s
o
n
-
y
e
a
r
s
 
o
f
 
f
o
l
l
o
w
-
u
p
.
 
C
I
 
=
 
c
o
n
f
i
d
e
n
c
e
 
i
n
t
e
r
v
a
l
;
 
R
R
 
=
 
r
a
t
e
 
r
a
t
i
o
.
†
 
R
R
s
 
w
e
r
e
 
g
e
n
e
r
a
t
e
d
 
w
i
t
h
 
a
 
P
o
i
s
s
o
n
 
r
e
g
r
e
s
s
i
o
n
 
m
o
d
e
l
 
t
h
a
t
 
h
a
d
 
a
n
 
i
n
t
e
r
a
c
t
i
o
n
 
b
e
t
w
e
e
n
 
f
o
l
l
o
w
-
u
p
 
g
r
o
u
p
 
i
n
d
i
c
a
t
o
r
 
(
0
 
i
f
 
K
S
 
w
a
s
 
d
i
a
g
n
o
s
e
d
 
i
n
 
t
h
e
 
c
A
R
T
 
f
o
l
l
o
w
-
u
p
 
g
r
o
u
p
,
 
1
 
i
f
 
K
S
 
w
a
s
 
d
i
a
g
n
o
s
e
d
 
i
n
 
t
h
e
 
n
a
i
v
e
 
f
o
l
l
o
w
-
u
p
 
g
r
o
u
p
)
 
a
n
d
 
C
D
4
 
s
t
a
t
u
s
 
w
i
t
h
 
a
d
j
u
s
t
m
e
n
t
 
f
o
r
 
a
g
e
.
Figure 1. Crude Kaposi sarcoma (KS) incidence rates according to time 
since initiation of combination antiretroviral therapy (cART). Confidence 
intervals (as shown by error bars) were computed by assuming a 
Poisson distribution for the number of events. cART naive = KS inci-
dence rates in patients who did not start cART; PY = person-years.jnci.oxfordjournals.org    JNCI | Articles 789
Discussion
To our knowledge, this is the first study to examine the associa-
tions of HIV infection duration and history of immunosuppression 
with risk of Kaposi sarcoma. We studied homosexual men with 
well-estimated dates of HIV seroconversion. In the cART follow-up 
group,  we  found  no  association  between  duration  of  infection   
or age and the incidence of Kaposi sarcoma but we did find that 
current CD4 cell count and current HIV RNA level were strongly 
associated with risk of Kaposi sarcoma.
The CD4 cell count at Kaposi sarcoma diagnosis appeared to 
increase over calendar time from a median of 106 cells per cubic 
millimeter for the 332 patients who were diagnosed before 1996 to 
a median of 252 cells per cubic millimeter for the 90 who were 
diagnosed in 2001–2006, indicating that approximately 50% of the 
cohort received their Kaposi sarcoma diagnosis at a CD4 count 
above  that  recommended  by  the  contemporaneous  treatment 
guidelines (ie, 200 cells per cubic millimeter) (26,27).
We found an overall reduction in the incidence of Kaposi sar-
coma in the cART follow-up group (8.22 Kaposi sarcoma events 
per 1000 person-years) compared with that in the naive follow-up 
group (3.58 Kaposi sarcoma events per 1000 person-years). At the 
same CD4 cell count strata, the risk of Kaposi sarcoma was higher 
in the naive follow-up group than in the cART follow-up group, 
particularly for a CD4 cell count if less than 200 cells per cubic 
millimeter,  indicating  that  the  risk  of  Kaposi  sarcoma  was  not 
completely  mediated  through  CD4  cell  count  and  that  other 
factors contribute to the risk of Kaposi sarcoma. We may have 
underestimated the incidence rates of Kaposi sarcoma in the high-
est CD4 count categories by assuming that the missing CD4 cell 
levels were more than 500 cells per cubic millimeter; however, this 
problem is unlikely to have affected the rate ratios.
We also found that over time both the CD4 cell count and the 
nadir for CD4 cell count at Kaposi sarcoma diagnosis shifted to 
higher  levels.  One  explanation  for  these  findings  is  that  the 
increased medical care that generally accompanies treatment with 
cART increases the opportunity for symptoms and lesions to be 
identified and examined at an early stage. Other explanations are 
that cART may not control human herpesvirus 8, which is consid-
ered a necessary cause of Kaposi sarcoma, and the causal relation 
between human herpesvirus 8 and Kaposi sarcoma development 
may not be directly mediated through the improvement of the 
immune system. Finally, the observed increase in CD4 cell levels 
at Kaposi sarcoma diagnosis may be due to a change in Kaposi 
sarcoma site because it has been reported (28) that the decline   
in Kaposi sarcoma incidence since the introduction of cART has 
affected Kaposi sarcoma with visceral involvement more strongly 
Table 3. Factors associated with Kaposi sarcoma incidence after combination antiretroviral therapy (cART) initiation*
Variable
Univariate analysis Multivariable analysis†
RR (95% CI) P‡ RR (95% CI) P
Per year of HIV infection duration 0.96 (0.90 to 1.02) .16 0.97 (0.90 to 1.05) .44
Per 10-y increase in current age 0.84 (0.63 to 1.13) .26 1.01 (0.74 to 1.39) .93
Current CD4 cell status      
  ≥500 cells per cubic millimeter 1 (ref.) <.001 1 (ref.) <.001
  350–499 cells per cubic millimeter 4.11 (1.74 to 9.70)   2.77 (1.12 to 6.85)
  200–349 cells per cubic millimeter 3.55 (1.40 to 9.00)   2.77 (1.07 to 7.20)
  <200 cells per cubic millimeter 18.91 (8.50 to 42.09)   11.34 (4.63 to 27.80)
Current HIV RNA status 1.31 (1.22 to 1.40) <.001 1.19 (1.10 to 1.29) <.001
Time since cART initiation      
  1 y 1 (ref.) .003 1 (ref.) .66
  >1 y 0.45 (0.27 to 0.76)   0.87 (0.47 to 1.61)
Type of cART      
  Non-protease inhibitor cART 1 (ref.) .99 1 (ref.) .44
  Protease inhibitor cART 1 (0.59 to 1.72)   0.80 (0.46 to 1.41)
Pre-cART status      
  Pretreated§ 1 (ref.) .67 1 (ref.) .16
  Naive to treatment 1.14 (0.63 to 2.05)   1.67 (0.82 to 3.41)
*  CI = confidence interval; ref. = referent; RR = rate ratio.
†  Variable adjusted for all other variables listed.
‡  Wald test. All statistical tests were two-sided.
§  Patients received other or suboptimal antiretroviral treatments before initiation of a combination antiretroviral therapy (cART).
Table 4. Relationship of nadir CD4 cell count to Kaposi sarcoma in 
homosexual men treated with combination antiretroviral therapy 
(cART)*
CD4 cell count RR (95% CI) P†
Current
  <200 cells per cubic millimeter 11.43 (3.62 to 36.06) <.001
  200–349 cells per cubic millimeter 3.17 (1.04 to 9.63)
  350–499 cells per cubic millimeter 2.93 (1.04 to 8.27)
  ≥500 cells per cubic millimeter 1 (ref.)
Nadir
  <100 cells per cubic millimeter 0.70 (0.23 to 2.13) .59
  100–199 cells per cubic millimeter 0.51 (0.17 to 1.52)
  200–349 cells per cubic millimeter 0.99 (0.45 to 2.21)
  ≥500 cells per cubic millimeter 1 (ref.)
*  Multivariable models were adjusted for duration of infection, current age, 
time since cART initiation, whether ART naive (yes or no), and whether 
treated with a protease inhibitor (yes or no). CI = confidence interval;  
nadir = lowest level recorded; ref. = referent; RR = rate ratio.
†  Wald test. All statistical tests were two-sided.790   Articles | JNCI  Vol. 102, Issue 11  |  June 2, 2010 
than cutaneous Kaposi sarcoma and that, among cART-treated 
patients, Kaposi sarcoma with nonvisceral involvement appears to 
be diagnosed at higher levels of CD4 cells than visceral Kaposi 
sarcoma.
As previously reported (5,7), we also found that most Kaposi 
sarcoma diagnoses among patients who were being treated with 
cART occurred during the first year of therapy (ie, 26 of the 70 
Kaposi sarcoma diagnoses), with a high Kaposi sarcoma incidence 
rate at 6.5 events per 1000 person-years. Some of these events may 
be  due  to  the  immune  reconstitution  inflammatory  syndrome, 
which has been linked to detection of rare cases of Kaposi sarcoma 
among individuals after the initiation of cART (29–31). The im-
mune reconstitution inflammatory syndrome consists of a clinical 
deterioration after the initiation of cART that is believed to be a 
consequence of restored ability to mount an inflammatory response. 
Connick et al. (30) suggested that Kaposi sarcoma–associated im-
mune  reconstitution  inflammatory  syndrome  may  be  more 
common than is reflected in the literature because Kaposi sarcoma– 
associated immune reconstitution inflammatory syndrome can be 
misdiagnosed as Kaposi sarcoma development caused by treatment 
failure.  Given  that  the  development  of  cancers  is  preceded  by 
exposure to the causative agent by many years, however, it may not 
be appropriate to attribute Kaposi sarcoma diagnosis at such an 
early stage in treatment with cART to cART itself. Indeed, among 
those  in  the  naive  follow-up  group,  Kaposi  sarcoma  rate  was 
slightly higher at 8.22 events per 1000 person-years, but we found 
no evidence to indicate that rates of Kaposi sarcoma increased after 
cART  was  initiated.  Moreover,  in  the  second  year  after  cART 
initiation, we detected a sharp fall in the incidence of Kaposi sar-
coma  that  appeared  to  remain  stable  thereafter.  Our  findings, 
therefore, suggest that Kaposi sarcoma diagnosed in the first year 
is unlikely to be related wholly to immune reconstitution inflam-
matory syndrome.
It may also be that the decline observed after the first year of 
cART treatment is a result of bias due to underascertainment of 
men diagnosed with Kaposi sarcoma after the initiation of cART. 
However, in the multivariable model after adjustment for current 
CD4 cell count, no association between the rate of Kaposi sar-
coma and the duration of cART was observed, indicating that the 
higher rate in the first year may be explained by the low CD4 cell 
counts  in  patients  who  have  recently  initiated  treatment  with 
cART. Such recording bias is unlikely, therefore, to fully explain 
this decline.
The risk of Kaposi sarcoma appeared to be similar among men 
treated with protease inhibitor in their initial cART regimen and 
those treated with non-protease inhibitor–containing cART. This 
result is in conflict with results of two previous studies (32,33) that 
promoted the use of protease inhibitors as potent antiangiogenic 
and antitumor molecules but is supported by the results of four 
cohort studies (7,12,28,34), however, that may have been subject to 
confounding by indication. Our data do not, therefore, support the 
preferential use of protease inhibitors in cART regimens for the 
treatment of HIV-infected men at risk of Kaposi sarcoma.
The persistence or development of Kaposi sarcoma in HIV-
infected men on cART despite high CD4 counts and undetectable 
HIV  RNA  has  been  reported  by  several  authors  (13–16).  This 
observation was confirmed by our finding of nine men who were 
diagnosed with Kaposi sarcoma when they had a CD4 cell count of 
more than 300 cells per cubic millimeter and a level of HIV RNA 
that had remained at less than 500 copies per milliliter for at least 
2 years after the initiation of cART.
Although age is an established risk factor for the development 
of classic Kaposi sarcoma, which usually occurs in individuals who 
are older than 50 years (20), increasing age was not associated with 
risk of Kaposi sarcoma among HIV-seropositive patients who had 
initiated cART. One explanation for this finding may well be the 
limited  and  young  age  range  of  our  participants  (median  =  37 
years, IQR = 32–42 years) so that we could not study associations 
among older men. This possibility is supported by a study (35) 
from the French Hospital Database that found a moderate associ-
ation between age and risk of Kaposi sarcoma among individuals 
who  were  older  than  60  years  compared  with  those  who  were 
younger than 30 years, with the strength of the association being 
only marginally increased among those aged 30–59 years.
Treatment with cART among patients with Kaposi sarcoma has 
been associated with improved survival (36) and prolonged time to 
treatment failure (37). Data from this study support this increased 
survival. The prognosis among HIV-infected cancer patients tends 
to be worse than that among non-HIV cancer patients (38–40). It 
is not clear, however, whether this is because of an overall lack of 
contact with medical services, leading to a late diagnosis of both 
HIV and cancer, or whether cancer is more aggressive in the pres-
ence of HIV infection. Although our survival estimates for patients 
with chronic HIV infection of 24 months before 1996 (ie, 35% 
alive)  were  similar  to  those  from  studies  (ie,  29%–49%  alive) 
(36,41–44), it is noteworthy that, in the period of 1996–2000, we 
found more favorable survival estimates (84% alive) than other 
studies (61%–66% alive). Only one study (45) that was based on 
data  from  seroprevalent  patients  reported  better  survival  at   
36 months. Thus, overall, the homosexual men in this study appear 
to have benefited from being diagnosed and monitored early in 
HIV infection.
This  study  had  several  limitations  that  should  be  discussed. 
First, we did not have information on treatment adherence and, 
therefore, assumed that patients remained on therapy once it was 
initiated. If diagnoses of Kaposi sarcoma are largely occurring in 
individuals who have stopped using cART or have poor adherence 
to the treatment regimen, then the incidence of Kaposi sarcoma in 
the cART follow-up group will have been overestimated. To eval-
uate this possibility, we performed sensitivity analyses considering 
follow-up time for those in the cART follow-up group whose HIV 
RNA level remained at less than 1000 copies per milliliter. This 
analysis had no effect on estimates of the associations of HIV in-
fection duration, age, or current CD4 levels with risk of Kaposi 
sarcoma (data not shown).
Second, in the cART follow-up group, associations between var-
ious factors and risk of Kaposi sarcoma were based on only 70 Kaposi 
sarcoma events and a limited median follow-up of 4.5 years (IQR = 
1.9–7.3 years). Thus, because of the small number of events, this 
analysis may have lacked the power to detect associations between 
duration of infection, age, or nadir CD4 cell count and risk of Kaposi 
sarcoma. However, because we did find associations between current 
CD4 cell count and risk of Kaposi sarcoma, we concluded that, if an 
effect of duration of infection, age, or nadir CD4 cell count exists, it jnci.oxfordjournals.org    JNCI | Articles 791
should be smaller than the effect of the current level of immunosup-
pression (as measured by CD4 cell count).
Third, when we compared risk of Kaposi sarcoma between the 
naive follow-up group and the cART follow-up group, our esti-
mates may have been biased through confounding by indication 
(ie, men who start cART are more likely to be sicker and at higher 
risk of Kaposi sarcoma). Confounding by indication would have 
led to an overestimate for the risk of Kaposi sarcoma among those 
in the cART follow-up group and would thus tend toward esti-
mating similar rates in the naive and cART follow-up groups.
Finally, the observed increase in survival may have indicated 
that patients in later years have had less aggressive form of Kaposi 
sarcoma or that death from non-Kaposi sarcoma causes has been 
reduced. Unfortunately, information on whether death was caused 
by Kaposi sarcoma is not recorded in the CASCADE dataset.
In conclusion, in this study of homosexual men with a known 
date of HIV seroconversion, we found that duration of HIV infec-
tion, age, or nadir CD4 cell count was not associated with inci-
dence of Kaposi sarcoma in treated men after adjustment for CD4 
cell  count.  We  also  found  that,  in  the  cART  follow-up  group, 
Kaposi sarcoma tended to be diagnosed at a higher CD4 cell count 
than that in the naive follow-up group and that survival after a 
diagnosis of Kaposi sarcoma has increased in the cART follow-up 
group. It may also be worthwhile screening at risk men for human 
herpesvirus 8 so that they can be monitored more frequently for 
signs of Kaposi sarcoma, even if they have a relatively high CD4 
cell count. Finally, given the high survival estimates in this analysis, 
compared with results from studies (36,41–44) that were based on 
seroprevalent patients, early diagnosis of HIV infection may be 
associated with better prognosis of Kaposi sarcoma.
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